These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25529343)

  • 1. CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
    Jeong TD; Kim SM; Kim HJ; Lee W; Kwon SU; Min WK; Kang DW; Chun S
    J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):440-6. PubMed ID: 25529343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
    CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
    Fang L; Zhao Y; Wang N; Yang Z; Huang H; Lin M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):871-6. PubMed ID: 26663068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
    Han SW; Kim YJ; Ahn SH; Seo WK; Yu S; Oh SH; Kim YN; Lee KY;
    Int J Stroke; 2016 Jun; 11(4):485-91. PubMed ID: 26763917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
    Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
    J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
    Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
    J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
    Song TJ; Kim J; Han SW; Kim YD; Lee JY; Ahn SH; Lee HS; Jung YH; Lee KY
    BMJ Open; 2020 Aug; 10(8):e038031. PubMed ID: 32759249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention.
    Liu G; Yang S; Chen S
    Medicine (Baltimore); 2020 Mar; 99(11):e19143. PubMed ID: 32176040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
    Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y
    Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
    Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM
    Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
    Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
    JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
    Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
    Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
    Wang Y; Cai H; Zhou G; Zhang Z; Liu X
    J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Yi X; Zhou Q; Wang C; Lin J; Chai Z
    J Neurol; 2018 Oct; 265(10):2396-2403. PubMed ID: 30128710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
    McDonough CW; McClure LA; Mitchell BD; Gong Y; Horenstein RB; Lewis JP; Field TS; Talbert RL; Benavente OR; Johnson JA; Shuldiner AR
    J Am Heart Assoc; 2015 May; 4(6):e001652. PubMed ID: 26019129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.